Tuesday, October 11, 2011 10:19:33 PM
The problem in my opinion with CGAQ and it's Price per share is, that the press releases
are poorly written. That together with the dilution of shares as well as the free trading
shares that CGAQ sold in the past to investors at a very low price, keeps the PPS low.
I said this over 6 months ago and I repeat. This stock when compared to other penny stocks
in the market, should be selling for .25 cents or better, racetrack or no racetrack. This is not
a shell company, but for all intents and purposes it acts like one.
This is a problem that Mr. Swank apparently can't get through his head, and it's not just me
saying it. I picked up on it, when others commented over it. Other posters like "SPRYCEL'
"Rleo", "juschilln" and others have brought this out months ago. I mention this three because
they have virtually stopped posting and you can't blame them.
Just read the last two P.R.'s and you can't help saying to yourself, who wrote this idiotic
comments. On the 09/09/2011 he insults some of the shareholders and then tells us that
going from the Hipodromo V Centenario racetrack to the Hotel is "a more upscale location"
To me he is telling us in a round about way, instead of been straightforward we are not
getting the racetrack. OK so maybe the stock wont go up to $$$$ but we still have a lot
going for CGAQ. In my opinion doing it the way he goes about in telling us, hurts the stock
and no Chart in my opinion is going to be able to properly give us an estimate of how the
PPS. is going to go.
If he just gave a good honest press release, without exaggerations, this stock will go up in
price, perhaps not the $ sign but a good .10, .15 0r more and that for now will be good
enough for most of us.
are poorly written. That together with the dilution of shares as well as the free trading
shares that CGAQ sold in the past to investors at a very low price, keeps the PPS low.
I said this over 6 months ago and I repeat. This stock when compared to other penny stocks
in the market, should be selling for .25 cents or better, racetrack or no racetrack. This is not
a shell company, but for all intents and purposes it acts like one.
This is a problem that Mr. Swank apparently can't get through his head, and it's not just me
saying it. I picked up on it, when others commented over it. Other posters like "SPRYCEL'
"Rleo", "juschilln" and others have brought this out months ago. I mention this three because
they have virtually stopped posting and you can't blame them.
Just read the last two P.R.'s and you can't help saying to yourself, who wrote this idiotic
comments. On the 09/09/2011 he insults some of the shareholders and then tells us that
going from the Hipodromo V Centenario racetrack to the Hotel is "a more upscale location"
To me he is telling us in a round about way, instead of been straightforward we are not
getting the racetrack. OK so maybe the stock wont go up to $$$$ but we still have a lot
going for CGAQ. In my opinion doing it the way he goes about in telling us, hurts the stock
and no Chart in my opinion is going to be able to properly give us an estimate of how the
PPS. is going to go.
If he just gave a good honest press release, without exaggerations, this stock will go up in
price, perhaps not the $ sign but a good .10, .15 0r more and that for now will be good
enough for most of us.
Recent BSEM News
- BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor • GlobeNewswire Inc. • 05/22/2026 11:00:00 AM
- BioStem Technologies Announces Notice of Allowance for Four U.S. Design Patent Applications Covering Fenestrated Human Placental Allografts and One European Patent • GlobeNewswire Inc. • 05/20/2026 01:00:00 PM
- BioStem Technologies Reports First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/14/2026 08:05:00 PM
- BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026 • GlobeNewswire Inc. • 04/30/2026 08:05:00 PM
- BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer • GlobeNewswire Inc. • 04/30/2026 11:00:00 AM
- BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026 • GlobeNewswire Inc. • 04/08/2026 11:00:00 AM
- BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2026 08:05:00 PM
- BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025 • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM
- BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/24/2026 08:05:00 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 03:40:56 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026 • GlobeNewswire Inc. • 03/11/2026 08:05:00 PM
- BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference • GlobeNewswire Inc. • 02/20/2026 12:00:00 PM
- BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business • GlobeNewswire Inc. • 01/21/2026 10:30:00 PM
- BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 01/07/2026 09:05:00 PM
- BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 12/18/2025 12:00:00 PM
- BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference • GlobeNewswire Inc. • 12/10/2025 12:00:00 PM
- BioStem Technologies Expands Product Access in Medicaid • GlobeNewswire Inc. • 11/25/2025 01:59:13 PM
- BioStem Technologies Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/13/2025 09:02:00 PM
- BioStem Technologies Announces Filing of Restated Financial Statements • GlobeNewswire Inc. • 11/13/2025 09:01:00 PM
- BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes • GlobeNewswire Inc. • 11/05/2025 09:05:00 PM
- BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters • GlobeNewswire Inc. • 11/05/2025 12:00:00 PM
- BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers • GlobeNewswire Inc. • 10/31/2025 11:00:00 AM
- BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025 • GlobeNewswire Inc. • 10/30/2025 08:05:00 PM
